Abstract
Unanticipated results from 2 recent candidate human immunodeficiency virus type 1 (HIV-1) vaccine regimens in large-scale international trials highlight the importance of understanding the optimal earliest immune defense against HIV-1 infection. Presented here are key findings in these vaccine studies with relevance to the development of future vaccines to control acute HIV-1 infection.
Full Text
Accepted Version (
Free)
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call